Day: April 2, 2020

MONTREAL, April 02, 2020 (GLOBE NEWSWIRE) — ELIXXER, LTD. (TSX.V: ELXR  OTCQB: ELIXF  GR: 2LQA) (“ELXR” or the “Company”) is pleased to announce that Little Green Pharma continues to closely monitor progress of the COVID-19 pandemic and provided the following update on its key response activities.Key actionsLittle Green Pharma (LGP) has taken actions to protect the health and welfare of staff, maintain cultivation and manufacturing operations, review its cost base, manage cost exposure and counterparty risk, apply for cost relief and Government assistance where available, and secure supply chains of critical materials and consumables.LGP’s office-based staff have successfully moved to a remote working model, while the cultivation and manufacturing teams continue to operate at their respective facilities in accordance with COVID-19...

CALGARY, Alberta, April 02, 2020 (GLOBE NEWSWIRE) — FLYHT Aerospace Solutions Ltd. (TSX-V: FLY) (OTCQX: FLYLF) (the “Company” or “FLYHT”) announces preliminary first quarter 2020 highlights and sets fourth quarter and fiscal year 2019 conference call for Thursday, April 9, 2020 at 7:00 a.m. MDT (9:00 a.m. EDT).First Quarter 2020 Preliminary HighlightsSecured an aggregate US $4.6 million in sales contracts and purchase orders, assuming the Company provides services over the full term of these contractsExpanded Supplemental Type Certificate (STC) portfolioReported sales order backlog of approximately $52 million1Promoted seasoned aviation executive Derek Taylor to Vice President, Sales and Marketing (previously announced March 3, 2020)Provided worldwide meteorological organizations a temporary, free license to utilize Tropospheric...

OLNEY, Md., April 02, 2020 (GLOBE NEWSWIRE) — Sandy Spring Bancorp, Inc. (Nasdaq: SASR) will announce its first quarter earnings on Thursday, April 23, 2020. The company will hold a conference call that day at 2:00 p.m. (ET) to discuss results and answer questions. The conference call will be webcast live through the Sandy Spring Bank website.  Those who wish to participate in order to ask questions may do so by calling 1-866-235-9910; a password is not necessary.  Those who wish to listen to the call should go to the Investor Relations page of www.sandyspringbank.com and log on 10 minutes ahead of the scheduled start of the call. An internet-based replay will be available on the Investor Relations page of the website until May 7, 2020. A telephone voice replay will also be available during that same time period at 1-877-344-7529....

WOBURN, Mass., April 02, 2020 (GLOBE NEWSWIRE) — Replimune Group Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced the appointment of Dieter Weinand as Chairman of the Board of Directors and the new appointment of Paolo Pucci to the Board of Directors, effective immediately. Mr. Weinand succeeds Philip Astley-Sparke who in January transitioned from part time Executive Chairman to full time Chief Executive Officer.“We are pleased to announce these changes to our Board. Dieter has served on the Replimune Board since June 2018 and I am delighted he has agreed to step up to the Chairman role following my appointment as Chief Executive Officer,” said Philip Astley-Sparke, Chief Executive Officer of Replimune. “Both Dieter and Paolo bring to Replimune...

Piraeus, April 02, 2020 (GLOBE NEWSWIRE) — Delivery of the GasLog WindsorGasLog Ltd. (“GasLog” or “the Company”) (NYSE: GLOG) yesterday took delivery of the GasLog Windsor, a 180,000 cubic meter cargo capacity LNG carrier with X-DF propulsion and Mark III Flex containment system. Despite the industrial disruption in South Korea caused by the COVID-19 outbreak, the vessel was delivered on time and on budget. It will immediately commence a seven-year charter with a wholly owned subsidiary of Centrica plc.Operational UpdateGasLog and GasLog Partners LP (“GasLog Partners” or the “Partnership” and together with GasLog, the “Group”) (NYSE: GLOP) remain focused on securing the health and safety of their employees whilst ensuring safe and reliable operations for their customers and the global natural gas supply chain. To date, there have...

RedHill to promote Movantik® in the U.S. to expanded call points, including gastroenterologists, primary care physicians and additional specialists, along with Talicia® and Aemcolo®Movantik® generated U.S. net sales of $96 million in 2019TEL-AVIV, Israel and RALEIGH, N.C., April 02, 2020 (GLOBE NEWSWIRE) — RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company focused on gastrointestinal diseases, today announced that it has completed the recently announced acquisition of the global rights, excluding Europe, Canada and Israel, to Movantik® (naloxegol)1, for the treatment of opioid-induced constipation (OIC)2 from AstraZeneca (LSE/STO/NYSE: AZN).“We are expanding the promotion of Movantik® with our current sales force of approximately 100 sales representatives. Given the excellent...

Piraeus, April 02, 2020 (GLOBE NEWSWIRE) — Delivery of the GasLog WindsorGasLog Ltd. (“GasLog” or “the Company”) (NYSE: GLOG) yesterday took delivery of the GasLog Windsor, a 180,000 cubic meter cargo capacity LNG carrier with X-DF propulsion and Mark III Flex containment system. Despite the industrial disruption in South Korea caused by the COVID-19 outbreak, the vessel was delivered on time and on budget. It will immediately commence a seven-year charter with a wholly owned subsidiary of Centrica plc.Operational UpdateGasLog and GasLog Partners LP (“GasLog Partners” or the “Partnership” and together with GasLog, the “Group”) (NYSE: GLOP) remain focused on securing the health and safety of their employees whilst ensuring safe and reliable operations for their customers and the global natural gas supply chain. To date, there have...

Seven presentations by AC Immune and its partners at AAT-AD/PD™New data on early-stage TDP-43 and alpha-synuclein therapeutic and diagnostic candidates A lead anti-alpha-synuclein therapeutic antibody candidate has advanced into preclinical development to treat Parkinson’s disease and other synucleinopathiesLAUSANNE, Switzerland, April 02, 2020 (GLOBE NEWSWIRE) — AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company today outlined new preclinical data that will be presented at this year’s first ever online AAT-AD/PD™ Focus Meeting from April 2–5, 2020. The presentations describe proof-of-concept preclinical data for lead candidates in AC Immune’s therapeutic and diagnostic programs targeting TDP-43 and alpha-synuclein. These pathological proteins represent targets of increasing interest for the treatment...

CAMBRIDGE, Mass., April 02, 2020 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today provided a business update in the context of the developing situation with the COVID-19 (coronavirus) pandemic.“During the unprecedented challenges we all face with the SARS-CoV-2 pandemic, we have recently implemented plans to protect the safety, health and well-being of the patients, families and healthcare professionals involved in our clinical development programs, as well as our employees,” said Robert J. Gould, Ph.D., Fulcrum’s president and chief executive officer. “A number of our clinical trial sites are temporarily postponing trial-related activities in the wake of COVID-19. While we are fully focused...

NEW YORK, April 02, 2020 (GLOBE NEWSWIRE) — ArTara Therapeutics, Inc. (Nasdaq: TARA), a development-stage clinical biopharmaceutical company developing treatments for rare and specialty diseases with significant unmet needs, today announced the grants of inducement non-qualified stock options to purchase an aggregate of 51,650 shares of common stock to four new employees.Each stock option has an exercise price per share equal to $24.25 per share, ArTara’s closing trading price on April 1, 2020, the grant date, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the applicable vesting date and 1/48th of the underlying shares vesting monthly thereafter over 36 months subject to the new employee’s continued service relationship with ArTara through the applicable vesting dates.The...